Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the ...
MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T ...
Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation and immunology (I&I), will present a ...
The deubiquitinase USP17LA negatively regulates T-cell activation and attenuates anti-tumor immunity
USP17LA loss enhances T-cell function and anti-tumor activity in murine tumor models. Usp17la-deficient T cells exhibit ...
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and ...
For decades, diagnosis of brain cancer has been medicine’s most difficult and hazardous challenge. Simple imaging such as MRI ...
To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T persistence and function. Additionally, there is a growing trend towards ...
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...
Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback